SCM
CARM

Sarissa Capital Management’s Carisma Therapeutics CARM Stock Holding History

Sarissa Capital Management’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-2,060
Closed -$99K – 18
2015
Q3 		$99K Hold
2,060
– – 0.02% 18
2015
Q2 		$116K Hold
2,060
– – 0.03% 16
2015
Q1 		$368K Hold
2,060
– – 0.08% 17
2014
Q4 		$489K Buy
+2,060
New +$462K 0.17% 15

Other funds holding CARM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
FV2GP
Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM
FVFIGP
Flagship Ventures Fund IV General Partner Cambridge, Massachusetts $585M AUM
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RCM
Rotella Capital Management Bellevue, Washington $1.47M AUM 12.32% 1-Year Est. Return

Sarissa Capital Management's CARM Position: Q4 2015 in Review

Sarissa Capital Management sold out of Carisma Therapeutics (CARM) in Q4 2015, closing a stake of 2,060 shares — an estimated $99K sold.

Sarissa Capital Management first reported a position in CARM in Q4 2014 and held it in 4 quarters. The position peaked at $489K in Q4 2014. 29 funds tracked by Wall St. Rank hold CARM as of Q4 2015.

  • Sarissa Capital Management reported no remaining Carisma Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Sarissa Capital Management sold 2,060 Carisma Therapeutics shares in Q4 2015, an estimated $99K.
  • Sarissa Capital Management first reported a position in Carisma Therapeutics in Q4 2014 and held it in 4 quarters.
  • Sarissa Capital Management's Carisma Therapeutics position peaked at $489K in Q4 2014.
  • 29 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2015.

Based on Sarissa Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.